id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-D-0697-0001,FDA,FDA-2022-D-0697,Sameness Evaluations in an Abbreviated New Drug Application—Active Ingredients; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2022-11-09T05:00:00Z,2022,11,2022-11-09T05:00:00Z,,2022-11-09T13:49:02Z,2022-24432,0,0,090000648549d539
FDA-2022-D-0697-0002,FDA,FDA-2022-D-0697,Sameness Evaluations in an Abbreviated New Drug Application—Active Ingredients; Draft Guidance for Industry; Availability,Other,Guidance,2022-11-09T05:00:00Z,2022,11,2022-11-09T05:00:00Z,2023-01-10T04:59:59Z,2024-11-07T00:43:32Z,,1,0,090000648549d3b7